Compounds > vadimezan
Page last updated: 2024-09-03

vadimezan and Fibrosarcoma

vadimezan has been researched along with Fibrosarcoma in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bellnier, DA; Cheney, RT; Seshadri, M1
Bellnier, DA; Camacho, SH; Cheney, RT; Gollnick, SO; Greco, WR1
De Witte, PA; Ni, Y; Van de Putte, M1
Laux, WT; Palmer, BN; Rutland, MD; Siim, BG; Wilson, WR1

Other Studies

4 other study(ies) available for vadimezan and Fibrosarcoma

ArticleYear
Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.
    International journal of radiation oncology, biology, physics, 2008, Nov-15, Volume: 72, Issue:4

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Contrast Media; Female; Fibrosarcoma; Image Enhancement; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Treatment Outcome; Xanthones

2008
Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Cancer research, 2003, Nov-15, Volume: 63, Issue:22

    Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Dihematoporphyrin Ether; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Fibrosarcoma; Mice; Mice, Inbred C3H; Necrosis; Neoplasms, Experimental; Photochemotherapy; Tumor Necrosis Factor-alpha; Xanthones

2003
Exploration of the mechanism underlying the tumor necrosis avidity of hypericin.
    Oncology reports, 2008, Volume: 19, Issue:4

    Topics: Animals; Anthracenes; Carbocyanines; Female; Fibrosarcoma; Lipoproteins; Mice; Mice, Inbred C3H; Necrosis; Perylene; Sarcoma, Experimental; Xanthones

2008
Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic
    Cancer research, 2000, Aug-15, Volume: 60, Issue:16

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Hypoxia; Fibrosarcoma; Humans; Mammary Neoplasms, Experimental; Melanoma; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms, Experimental; Organotechnetium Compounds; Oximes; Radionuclide Imaging; Radiopharmaceuticals; Stilbenes; Xanthenes; Xanthones

2000